What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Portfolio Pulse from Benzinga Insights
4D Molecular Therapeutics (NASDAQ:FDMT) has received six bullish analyst ratings in the last quarter, with an average price target of $33.67, indicating a potential upside from the current price of $18.3. The average price target has increased by 16.1% over the past month.
July 31, 2023 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics has received positive analyst ratings, suggesting a potential upside.
The company has received six bullish analyst ratings in the last quarter, indicating a positive outlook. The average price target of $33.67 is significantly higher than the current price of $18.3, suggesting a potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100